Naomi Koenig, APRN
Psychiatric/Mental Health · Sandstone, MNNPI 1659893170
Payments from drug & device makers
What this record shows
This record is dominated by other: $5,734 of the $7,641 with a category attached, or 75.0%. Neuronetics, Inc. accounts for 91.0% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $5,973, more than ten times the $107 reported in 2021. Among psychiatric/mental health clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $169.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$7K
- Supernus Pharmaceuticals, Inc.$158
- Neurocrine Biosciences, Inc.$66
- AstraZeneca$62
- Tempus AI, Inc$52
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50
- plus $302 from 15 others
What the payments were for
- Travel & lodging$6819%
- Food & beverage$1,22616%
- Other$5,73475%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 4 | $6,950 |
| Supernus Pharmaceuticals, Inc. | 7 | $158 |
| Neurocrine Biosciences, Inc. | 4 | $66 |
| AstraZeneca | 4 | $62 |
| Tempus AI, Inc | 2 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Astellas Pharma US Inc | 3 | $46 |
| Boehringer Ingelheim | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $28 |
| Novo Nordisk | 2 | $27 |
| AbbVie | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Organon | 1 | $15 |
| GSK | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Corium, LLC | 1 | $13 |
| Incyte Corporation | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,641 in reported general payments places this provider in the 95th percentile of 407 psychiatric/mental health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $62,941 |
| JardianceEmpagliflozin | 45 | $33,451 |
| OzempicSemaglutide | 28 | $26,352 |
| EliquisApixaban | 30 | $25,925 |
| RexultiBrexpiprazole | 24 | $25,175 |
| TrulicityDulaglutide | 22 | $24,561 |
| EntrestoSacubitril/Valsartan | 22 | $19,364 |
| XareltoRivaroxaban | 23 | $15,822 |
| FarxigaDapagliflozin Propanediol | 20 | $13,783 |
| Xtampza ErOxycodone Myristate | 24 | $10,006 |
| MyrbetriqMirabegron | 16 | $7,311 |
| Paliperidone ErPaliperidone | 12 | $7,309 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 43 | $4,041 |
| Potassium Chloride | 24 | $3,551 |
| Clomipramine Hcl | 17 | $3,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $28 | $87,50270 claims |
| Boehringer IngelheimJardiance | $34 | $33,45145 claims |
| Novo NordiskOzempic | $27 | $26,35228 claims |
| AstraZenecaFarxiga | $62 | $13,78320 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $7,31116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 407 psychiatric/mental health providers in Minnesota.
Other psychiatric/mental health in Sandstone
- Jacqualine GervaisMoorhead$29K
- Dana BageonWayzata$7K
- Jill ScottAnoka$5K
- Holly WillisMinneapolis$5K
- Gerard BalanMinneapolis$5K
- Hilary BreedonShakopee$3K
- Tina AlexanderEdina$3K
- Twilla OskeyBaxter$3K
- Sara OckerCambridge$3K
- Patrick DixonAnoka$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.